CHR Researchers Make Surprising Discovery for Ovarian and Breast Cancer Screening

We have the pleasure of announcing today the results of our exciting new study which will potentially open the doors to less expensive and more accessible genetic screening for breast and ovarian cancers.

The results of the study, which was published in the prestigious online medical journal PLoS ONE, revealed a link between the “breast cancer susceptibility genes” (BRCA1 and BRCA2), and a very specific sub-genotype of the FMR1 gene known as “low.

The discovery of the connection between the two genes may have a significant impact not only on future genetic screening for breast and ovarian cancers, but also on cancer treatment methods and understanding the mystery of the “BRCA-paradox.”

Click to read the full press release about the study results and implications

 

Dr. Norbert Gleicher and Dr. David Barad of the CHR worked in collaboration with teams of researchers from the Medical University Vienna, in Vienna, Austria and the Medical University Graz, in Graz, Austria, on this study.